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Background: Pharmaceutical care is one of the major tasks of pharmacists, which aims to 
improve patient outcomes. Counseling patients with asthma or chronic obstructive pulmonary 
disease about their use of inhaled corticosteroids (ICS) might enhance medication adherence 
and symptom control. Therefore, effective pharmacist–patient communication is very important. 
In this regard, both affective communication, for handling emotions, and instrumental 
communication, for exchanging biomedical and lifestyle information, are relevant. Until now, 
only few studies have explored pharmacist–patient communication, and further insight is needed 
in this regard. The aim of this study is to investigate how pharmacists and pharmacy techni-
cians communicate about ICS with patients with asthma and/or chronic obstructive pulmonary 
disease, what topics are discussed by them, and whether pharmacists and pharmacy technicians 
differ in their communication during counseling sessions.
Methods: Patients aged $18 years who had used ICS for at least 1 year and filled at least two 
ICS prescriptions in the preceding year were recruited through 12 pharmacies. Participants had 
one counseling session with a pharmacist or a pharmacy technician, which was video-recorded. 
The process and content of the provider–patient communication were analyzed using the Roter 
interaction analysis system, adapted to the pharmaceutical setting.
Results: A total of 169 sessions were recorded and analyzed. The communication appeared 
largely instrumental. Lifestyle, psychosocial issues, and ICS adherence were not discussed in 
detail. The pharmacists had longer conversations and more affective talk than the pharmacy 
technicians.
Conclusion: Pharmacists and pharmacy technicians may need to pay more attention to 
ICS adherence, lifestyle, and psychosocial topics. They differed in their communication; the 
pharmacists exhibited more affective behavior and discussed medical and therapeutic issues 
more extensively compared to the pharmacy technicians. Educational courses for pharmacists 
and pharmacy technicians could focus more on the discussion of adherence, lifestyle, and 
psychosocial topics with patients.
Keywords: community pharmacy, communication, inhaled corticosteroids, pharmacist–patient 
interaction, Roter interaction analysis system
Introduction
According to the Pharmaceutical Care Network Europe definition, “Pharmaceutical 
care is the pharmacist’s contribution to the care of individuals in order to optimize 
medicines use and improve health outcomes”.1 The community pharmacist’s role has 
recently been extended from just dispensing to providing guidance in pharmaceutical 
care. Several pharmaceutical care programs and activities have been developed to 
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educate and counsel patients with (chronic) medication use, 
showing some promising results in improving outcomes such 
as disease control and medication adherence.2–5
Patients with asthma and chronic obstructive pulmonary 
disease (COPD) could especially benefit from these activities. 
Around 40% of them fail to take their inhaled corticosteroids 
(ICS) as prescribed.6 Regular ICS treatment reduces symp-
toms and the frequency of exacerbations and enhances lung 
function and quality of life.7,8 Taking less medication than 
prescribed (suboptimal adherence) leads to poor disease 
control, morbidity, mortality, and high health care costs.6 
Many patients with asthma (17%–57%) do indeed have poor 
disease control,9 as shown by the high rates of emergency-
room visits and hospital admissions.10
Sufficient and correct knowledge about the disease 
and medication is needed to achieve better adherence to 
antiasthma drugs and have better asthma control.11,12 But the 
knowledge among patients with asthma appears suboptimal.13 
Many patients report taking their medication only when 
they think they should or when they experience shortness 
of breath.14 In addition, 70% of patients using ICS apply 
incorrect inhaler techniques that disenable total absorption 
of the medication in the lungs.15 Improving inhaler technique 
is likely to improve symptom control.16
Clearly, educating patients with asthma and COPD about 
their disease, medication use, and inhalation technique is of 
great importance in enhancing ICS adherence and symptom 
control. This is even more so as patients’ potentially modi-
fiable medication beliefs are related to ICS adherence.17–19 
Patients who have many concerns and misconceptions about 
ICS (eg, about side effects and drug dependency) are more 
inclined to be nonadherent. Therefore, health care providers 
should try to diminish patients’ concerns and strengthen their 
ICS necessity beliefs,17,19 by showing empathy and providing 
reassurance and information about ICS use and adherence. 
However, medication adherence is hardly addressed at all in 
clinical encounters,20,21 even though Zolnierek and Dimatteo22 
showed that the odds of patient adherence are 2.16 times 
higher when a physician communicates effectively.
To perform their new role as communicators, pharmacists 
and pharmacy technicians receive training in patient educa-
tion and communication in undergraduate and postgraduate 
courses.23 However, so far, little is known about the extent 
to which they actually apply these skills in counseling 
sessions.24 Recent research indicates that pharmacists focus 
mainly on biomedical issues and pay little attention to psy-
chosocial issues.25,26
In counseling sessions, pharmacists or technicians can 
discuss patients’ experiences with (chronic) medication, 
usually in a private consulting room at the community 
pharmacy. Although some pharmacies do offer counseling 
sessions to patients about their ICS use, these sessions are not 
common practice in the Netherlands yet.23,27 Furthermore, it 
is unknown whether pharmacists and technicians are equally 
able to conduct these sessions. For instance, there are dif-
ferences in the undergraduate and postgraduate courses 
for pharmacists and technicians. As technicians have more 
frequent contacts with patients than pharmacists,28 they might 
be more experienced in patient communication. A study of 
patients’ perceived barriers in communication with their 
health care provider revealed that patients experience fewer 
barriers to participation in a visit with a nurse than with a 
physician.29 This might also apply to pharmacists and techni-
cians, with fewer barriers in talks with technicians. However, 
pharmacists might have a more persuasive communication 
style by virtue of their position, as they are the managers and 
often owners of the pharmacy. Getting insight into the differ-
ences in the communication content and process might have 
relevance for session and patient outcomes and might indicate 
who is most capable of performing these counseling sessions 
and who might need additional communication training.
The aim of this study was therefore to explore 1) how 
pharmacists and pharmacy technicians communicate with 
patients with asthma and/or COPD about ICS during a 
counseling session (communication process); 2) what topics 
are discussed during these sessions (communication content); 
and 3) to what extent pharmacists and technicians differ in 
their communication. Based on practice guidelines about 
asthma and COPD, we thereby focus especially on the fol-
lowing communicative aspects:30–32 affective communication 
(eg, showing empathy and giving reassurance), provid-
ing information about asthma/COPD and ICS, discussing 
adherence, inhalation technique, side effects, concerns, and 
necessity beliefs about ICS, and lifestyle topics (eg, smoking 
and exercise).
Materials and methods
setting
This observational study is part of a larger research project 
examining the communication of community pharmacists 
and technicians with patients with asthma and/or COPD, 
which was performed between September 2011 and February 
2012. Data were collected with the help of pharmacists 
belonging to the Utrecht Pharmacy Practice Network for 
Education and Research (UPPER), and the work was 
conducted in compliance with the requirements of the 
UPPER institutional review board of the Department of 
Pharmacoepidemiology and Clinical Pharmacology. A total 
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of 130 community pharmacies were approached via email 
by UPPER and invited to participate, with 12 pharmacies 
actually participating. No selection criteria were applied for 
pharmacies’ participation.
Per pharmacy, recruited patients were randomly assigned 
to an intervention group or a control group. Randomiza-
tion was performed using a statistical program (Stata 
Version 12.1), which generated lists consisting of a random 
series of 0s and 1s. We generated a separate list for each 
pharmacy. A “0” referred to assignment to the control group, 
and a “1” referred to assignment to the intervention group. 
By following the order of the numbers on the list, patients 
were assigned to the two groups in the sequence of their 
registration for participation.
Patients in the intervention group had a counseling 
session at the community pharmacy; patients in the control 
group had no session and only completed questionnaires. For 
the purpose of this study, only data from patients who had 
a counseling session were used.
At each participating pharmacy, one pharmacist and 
one pharmacy technician performed individual counseling 
sessions with patients with asthma and/or COPD. Each 
pharmacist selected a pharmacy technician from his/her own 
team, so 12 pharmacists and 12 technicians held sessions. 
Each patient had one session with either a pharmacist or a 
pharmacy technician. The number of counseling sessions 
depended on the number of participating patients in that 
particular pharmacy and on an agreed maximum number of 
participants per pharmacy.
To get an authentic impression of pharmacists’ and 
technicians’ communication styles, only general instructions 
were provided about the counseling sessions, that is, “discuss 
the patient’s experience with ICS use, the effectiveness and 
(possible) side-effects of ICS, and whether the patient uses 
ICS in an appropriate way”.
ethical approval
The Medical Ethics Committee of the University Medical 
Center Utrecht assessed the research proposal and concluded 
that ethical approval was not required because the study did 
not fall within the remit of the Law on Medical Scientific 
Research involving Human Beings.
Participants
Patient recruitment took place through the participating 
pharmacies. Anatomical Therapeutic Chemical classifica-
tion system codes for ICS and combination products of 
β2-agonists and ICS were used to determine in the pharmacy 
system to which patients’ ICS had been dispensed. Patients 
were eligible if they were aged 18 years or older, had been 
diagnosed with asthma or COPD (based on self-report), had 
been using ICS for at least 1 year, and had filled two or more 
ICS prescriptions in the preceding year. Patients living in an 
institution were excluded because they might receive other 
or additional care and counseling, which might influence the 
generalizability of the study results. Patients did not receive 
a reimbursement for participation.
Procedure
At each pharmacy, all eligible patients were invited to partici-
pate in the study, up to a maximum of 200 patients per phar-
macy. If there were .200 eligible patients, a random subset 
of 200 patients were selected. An information pack was sent 
by post to 1,952 potentially eligible patients by their phar-
macist, containing an invitation letter, a questionnaire, and 
an informed consent form. Patients were informed about the 
procedure and the videotaping of the consultations, and they 
had the opportunity to ask questions about the study and the 
videotaping of the session before consenting to participation. 
The completed questionnaire and a signed informed consent 
form had to be returned for study participation. A researcher 
contacted the participants by phone to make an appointment 
for a counseling session with a pharmacist or technician 
within 2 months after inclusion. The schedules for phar-
macists and technicians had been determined beforehand. 
Depending on patients’ preferences for a date or time for an 
appointment, the consultation was scheduled. These sessions 
were performed in Dutch, took place in a private room, and 
were recorded by an unmanned camera, which was directed 
at the pharmacist or technician.
Materials and measurements
Questionnaire
The questionnaire consisted of questions about sociodemo-
graphics, the medical indication for the ICS prescription 
(asthma/asthma symptoms and/or COPD or unknown), and 
other questions related to the patient’s medical condition 
and ICS use.
communication measurements
Analyses of the video-recorded sessions were performed 
using an extended version of the Roter interaction analysis 
system (RIAS). RIAS is a validated instrument for coding 
both provider and patient communication, applicable to the 
pharmacy setting.33–35 Each small meaningful unit of speech 
(an utterance) is coded.
RIAS distinguishes two categories of communica-
tion: 1) affective or socioemotional communication and 
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2) instrumental communication, further divided into task- and 
process-oriented communication. Affective communication 
includes expressions of empathy, concern, optimism, and 
understanding, which contribute to a therapeutically effective 
provider–patient relationship.36 Instrumental communica-
tion focuses on the exchange of medical and psychosocial 
information and advice (task-oriented communication) and 
process-oriented utterances that guide the process of the 
conversation, like giving instructions (ie, “orientations”).
The four main task-oriented RIAS categories are 
1) medical, 2) therapeutic, 3) lifestyle/social, and 4) psy-
chosocial. For the purpose of this study, the task-oriented 
categories were further divided into 36 content categories, 
including asthma- and COPD-specific items derived from 
existing communication literature and guidelines for asthma 
and COPD,31 from the consumer quality index asthma/
COPD,30 and from the Dutch pharmacy COPD guideline.32 
This literature was used to indicate topics that are relevant 
for patients with asthma and/or COPD and that could be 
discussed during counseling sessions. Examples of specific 
medical and therapeutic content categories are medical 
history, current health status, ICS side effects, and ICS 
adherence. Each main category furthermore had one “residual 
category” for utterances that belonged to that particular main 
category but did not fit into any of the specified categories 
(ie, “medical, other”, “ICS, other”, “lifestyle, other”, and 
“psychosocial ICS, other”). Utterances about the study or 
comments about the recording were labeled as “other”. For 
each task-oriented utterance, it was established whether it 
concerned a question (“question”), the provision of informa-
tion (“giving information”), or an advice for the patient to 
change behavior (“counseling”) (Table S1).
Furthermore, the proportion of utterances made by the 
pharmacists, pharmacy technicians, and patients was deter-
mined as a global indicator of conversational contribution.
The videotapes were coded by three coders from the 
research team. Observer XT7 software was used to code the 
communication directly from the videotapes.37
interrater reliability
Interrater reliability was tested using the intraclass correlation 
coefficient (ICC) and calculated for all main categories with 
a mean frequency .2%, except for the “other” categories.38 
One coder recoded a random 10% of the two main coders’ 
consultations. ICC reliability averaged 0.85 (range 0.37–0.98) 
for pharmacist and technician categories and 0.89 (0.70–0.97) 
for patient categories, which indicates moderate to good reli-
ability, except for the category “orientations”, which had an 
ICC of 0.37. Given the low ICC of the orientations category, 
no results are reported for this category.
statistical analysis
Multilevel analysis was carried out to allow for the cluster-
ing of patients in pharmacies. Weighted mean and standard 
errors of all communication categories were calculated 
for pharmacists and technicians separately and have been 
reported. To control for visit length, weighted mean per 
category was divided by the total number of utterances and 
multiplied by 100%.
Furthermore, we calculated the number of sessions in 
which a particular content category was mentioned by the phar-
macist or the technician once only, more than once, or not at all, 
whether as a question, piece of advice, or information. Analy-
ses were performed using MLwiN Version 2.25. To determine 
whether patients’ sociodemographic characteristics differed 
between the pharmacists’ sample and those of pharmacy 
technicians, two-sample proportion tests and Student’s t-tests 
were performed using Stata Version 12.1. Descriptive statistics 
were calculated using Stata Version 12.1.
Results
study sample
A total of 429 patients returned a completed consent form 
and questionnaire. One hundred and ninety-nine patients 
were assigned to the intervention group, of whom 30 patients 
(15.1%) dropped out for one of the following reasons: they 
could not be reached by phone/email, involuntary withdrawal 
(eg, due to poor health), were no longer using ICS, had 
recently had a session about ICS or asthma, or did not want 
to participate after all. One hundred and sixty-nine patients 
received a counseling session at their pharmacy. Of these, 
93 patients (55.0%) were female and 76 (45.0%) male. The 
mean age was 63.1 years (SD =13.9). Half of the 12 phar-
macists were male and all the 12 technicians were female. 
The mean age of the pharmacists was 36.7 years (SD =11.5), 
and the mean age for technicians was 35.4 years (SD =11.9) 
(Table 1). The pharmacists performed 7.2 sessions on average 
(range: 3–11 sessions) and pharmacy technicians 6.9 sessions 
(range: 3–10 sessions). The sociodemographic characteristics 
of patients in the pharmacists’ sample did not differ signifi-
cantly from those in the pharmacy technicians’ sample.
counseling sessions
Pharmacists’ counseling sessions lasted significantly longer 
than those of pharmacy technicians (mean ± standard error: 
16.46±0.80 minutes and 11.34±0.80 minutes, respectively; 
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P,0.001). Both categories of professionals talked more than 
patients in terms of the percentage of utterances (pharmacists 
accounted for 55.0% of the utterances in their sessions, tech-
nicians 53.2%), and most of the communication consisted of 
instrumental talk (Table 1).
Affective and process-oriented 
communication
Table 2 shows the weighted mean of the affective and 
process-oriented communication behaviors per counseling 
session. Pharmacists and technicians mainly exhibited 
social behavior, expressed approval and agreement, and 
gave verbal attention and reassurance to patients. Patients 
showed similar behaviors and also expressed concerns or 
worries. With respect to process-oriented communication, 
pharmacists and technicians paraphrased and checked for 
understanding and asked the patient for an opinion at least 
once per session. Patients mainly paraphrased and checked 
for understanding.
Task-oriented communication
Several medical and therapeutic topics were discussed during 
the counseling sessions (Tables 3 and 4). In the following 
paragraphs, we describe the topics on which on average at 
least one utterance per session was made by pharmacists, 
technicians, or patients.
Medical and therapeutic communication
Pharmacists and technicians made at least one utterance per 
session about each of the following topics: “medical, other”, 
Table 1 Patient, pharmacist, and pharmacy technician characteristics and summary of pharmacist–patient and technician–patient 
communication
Pharmacist–patient 
sessions n=86
Technician–patient sessions 
n=83
Total n=169
Patient characteristics
Female 47 (54.7%) 46 (55.4%) 93 (55.0%)
Age, years
Mean (years) ± sD (range) 63.7±13.4 (26–88) 62.5±14.5 (28–87) 63.1±13.9 (26–88)
Age group, years
18–44 8 (9.3%) 12 (14.5%) 20 (11.8%)
45–64 32 (37.2%) 29 (34.9%) 61 (36.1%)
.64 46 (53.5%) 42 (50.6%) 88 (52.1%)
educational levela,b
low 33 (38.4%) 37 (44.6%) 70 (41.4%)
intermediate 17 (19.8%) 16 (19.3%) 33 (19.5%)
high 35 (40.7%) 29 (34.9%) 64 (37.9%)
Diagnosisc
Asthma 34 (39.5%) 34 (41.0%) 68 (40.2%)
cOPD 21 (24.4%) 21 (25.3%) 42 (24.9%)
Asthma and cOPD 17 (19.8%) 16 (19.3%) 33 (19.5%)
Unknown 14 (16.3%) 12 (14.5%) 26 (15.4%)
Pharmacists n=12 Pharmacy technicians n=12
Pharmacist and pharmacy technician characteristics
Age group, years
Mean (years) ± sD (range) 36.7±11.5 (24–57) 35.4±11.9 (23–53)
Female 6 (50%) 12 (100%)
number of years since graduating
Mean (years) ± sD (range) 11.1±10.4 (0–32) 14.4±11.8 (2–34)
Pharmacist–patient and pharmacy technician–patient communication
Pharmacist Patient Technician Patient
Total communicationd 55.0% 45.0% 53.2% 46.8%
Affective communication 20.2% 16.7% 19.4% 16.3%
instrumental communication 34.8% 28.3% 33.8% 30.5%
session length
Meane (minutes) ± se (range) 16.46±0.80 (5.42–33.30) 11.34±0.80 (4.23–26.73)
Notes: aTwo missing. blow: no education, primary school, prevocational secondary education (VMBO), lower vocational secondary education (lBO), junior general 
secondary education (MUlO/MAVO); intermediate: upper vocational secondary education (MBO), senior general secondary education (hAVO), preuniversity education 
(VWO); high: university of applied sciences (hBO), university (WO). cDiagnosis based on self-report. dPercentages are based on weighted mean. eWeighted mean.
Abbreviations: cOPD, chronic obstructive pulmonary disease; se, standard error.
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inhaler and inhalation technique, non-ICS treatment (other 
medication used by the patient), ICS medicinal effects, 
side effects, dosage and time of inhalation of ICS, current 
health status, adherence to ICS, reason for use, and “ICS, 
other”. In contrast to technicians, pharmacists also asked 
at least once about patients’ current health status and medi-
cal effects, and gave information about explanation about 
asthma/COPD more than once.
Patients made at least one utterance per session about the 
following issues: inhaler and inhalation technique, non-ICS 
medication, “medical, other”, dosage and time of inhalation, 
current health status, medical history, side effects, contact 
with health care providers about asthma/COPD, “ICS, 
other”, ICS medicinal effects, ICS adherence, lung function 
test, contact with other health care providers about ICS, and 
reason for use.
lifestyle and social context communication
Pharmacists gave some social context information, but 
other lifestyle and social context topics were not mentioned 
more than once. Patients gave information about physical 
activity, social context, the (living) environment, and 
“lifestyle, other”.
Psychosocial/feelings communication
Concerning psychosocial information, patients gave infor-
mation about how they felt about non-ICS medication and 
“ICS, other”. Pharmacists and technicians addressed almost 
no psychosocial topics.
Differences in communication between 
pharmacists and pharmacy technicians 
in their sessions
Below, we describe the differences between pharmacists 
and pharmacy technicians in communication during the 
counseling sessions. Only significant differences (P,0.05) 
are reported.
Pharmacists used more affective utterances per session 
on average than technicians. Patients did not differ in the 
number of affective utterances in their communication with 
pharmacists or technicians, except for giving agreements. 
Patients agreed more frequently in sessions with pharmacists 
than with technicians.
With respect to process-oriented communication, phar-
macists and technicians differed in the number of utterances 
paraphrasing/checking for understanding. Patients had the 
same number of process-oriented utterances during sessions 
with pharmacists and technicians.
Medical and therapeutic information
The pharmacists were more likely to ask questions about 
the following topics than the technicians: patients’ current 
health status, reason for ICS use, and other medication. 
Questions about side effects were asked more often by 
Table 2 Weighted mean (se) of affective behaviors and process-oriented behaviors of pharmacists, technicians, and patients in 
counseling sessions
Pharmacists’ and technicians’ 
behavior
Patients’ behavior
Pharmacists Technicians Pharmacists’ sessions Technicians’ sessions
Affective parta 89.02 (5.48)* 63.72 (5.53)* 73.55 (5.06)** 53.66 (5.12)**
social behavior 10.55 (1.68)** 4.86 (1.70)** 10.47 (2.01) 6.52 (2.04)
Approval 6.91 (0.56)* 3.68 (0.56)* 1.70 (0.24) 1.45 (0.24)
Agreements 59.95 (4.91)** 48.50 (4.94)** 54.54 (3.67)* 39.61 (3.71)*
Verbal attention 3.91 (0.56)** 2.00 (0.57)** 0.12 (0.04) 0.06 (0.04)
shows concern or worry 0.44 (0.09)*** 0.15 (0.10)*** 1.95 (0.37) 1.37 (0.38)
reassurance 7.77 (0.62)* 5.16 (0.63)* 3.82 (0.42) 3.40 (0.43)
Disagree 0.24 (0.05)** 0.05 (0.05)** 0.95 (0.57) 1.39 (0.57)
instrumental part
Process-orienteda 28.63 (2.15)* 21.45 (2.16)* 4.69 (0.62) 4.08 (0.62)
Orientationsb 8.26 (0.98)* 4.15 (0.98)* 0.28 (0.07) 0.14 (0.07)
Paraphrase/check for understanding 17.91 (1.70)*** 15.25 (1.70)*** 4.19 (0.57) 3.73 (0.57)
Bid for repetition 0.04 (0.02) 0.05 (0.02) 0.14 (0.05) 0.14 (0.05)
Ask for understanding 0.56 (0.13) 0.44 (0.13) 0.06 (0.03) 0.07 (0.03)
Ask for opinion 1.89 (0.26) 1.58 (0.26) 0.00 (0.01) 0.01 (0.01)
request for services 
(patient category)
– – 0.04 (0.02) 0.00 (0.02)
Notes: aTotals have been calculated using the model and can be different from the total of individual categories. bDue to a low intraclass correlation coefficient (ICC), 
no results have been reported in this article for this category. *Significant at P,0.001. **Significant at P,0.01. ***Significant at P,0.05.
Abbreviation: se, standard error.
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technicians than by pharmacists. Patients were more likely 
to ask questions about dosage and time of inhalation of 
ICS during sessions with pharmacists than with techni-
cians. Pharmacists were more likely to give information 
about a lung function test, asthma/COPD, reason for ICS 
use, dosage and time of inhalation, ICS effects, inhaler and 
inhalation technique, and other medication. Patients were 
more likely to provide information to pharmacists than 
technicians about the following topics: medical history, 
dosage and time of inhalation, and barriers. Technicians 
were more likely to give advice about ICS adherence than 
pharmacists.
Table 3 Weighted mean (se) of task-oriented behaviors of pharmacists and pharmacy technicians during counseling sessions
Task-oriented communication Question Giving information Counseling
Pharmacists Technicians Pharmacists Technicians Pharmacists Technicians
Medicala 3.42 (0.43)* 1.86 (0.43)* 9.25 (1.35)* 3.60 (1.36)* 0.50 (0.19) 0.44 (0.19)
Prevalence 0 0 0.06 (0.04) 0.00 (0.04) 0 0
Prognosis 0 0 0.02 (0.01) 0.00 (0.01) 0 0
exacerbations 0.06 (0.02) 0.00 (0.02) 0.06 (0.04) 0.04 (0.04) 0 0
current health status 1.31 (0.19)* 0.62 (0.19)* 1.87 (0.28) 1.31 (0.28) 0.00 (00.1) 0.01 (0.01)
Medical history 0.37 (0.10) 0.20 (0.10) 0.31 (0.08) 0.22 (0.08) 0 0
heredity 0.00 (0.05)** 0.09 (0.05)** 0.03 (0.05) 0.09 (0.05) 0 0
contact other health care 
providers about asthma/cOPD
0.49 (0.10) 0.54 (0.10) 0.53 (0.14) 0.37 (0.14) 0.15 (0.11) 0.39 (0.11)
lung function test 0.32 (0.10) 0.08 (0.10) 0.96 (0.32)** 0.13 (0.32)** 0.19 (0.08) 0.00 (0.08)
explanation about asthma/cOPD 0.01 (0.01) 0.00 (0.01) 2.65 (0.62)* 0.06 (0.63)* 0 0
Medical, other 0.85 (0.21)*** 0.33 (0.21)*** 2.74 (0.58) 1.47 (0.59) 0.15 (0.04) 0.05 (0.05)
Therapeutic: ics treatmenta 10.97 (0.87) 10.57 (0.87) 46.53 (3.17)* 33.42 (3.20)* 11.25 (1.45) 11.12 (1.46)
reason for use/need 0.45 (0.10)** 0.20 (0.10)** 1.03 (0.14)*** 0.54 (0.14)*** 0.05 (0.03) 0.05 (0.03)
Dosage 1.27 (0.16) 0.95 (0.16) 3.30 (0.35)* 1.27 (0.35)* 0.86 (0.17) 0.53 (0.17)
Adherence 0.42 (0.10) 0.45 (0.10) 1.38 (0.26) 1.21 (0.26) 0.17 (0.14)*** 0.49 (0.14)***
Medicinal effects 1.11 (0.23) 0.83 (0.23) 7.36 (0.75)* 3.30 (0.76)* 0.02 (0.01) 0.00 (0.01)
side effects 1.36 (0.29)** 1.90 (0.29)** 3.87 (0.56) 3.84 (0.57) 0.13 (0.04) 0.05 (0.04)
inhaler/inhalation 5.05 (0.48) 4.76 (0.48) 25.29 (2.24)*** 19.50 (2.26)*** 9.41 (1.41) 9.49 (1.42)
contact other health care 
providers about ics
0.40 (0.10) 0.55 (0.10) 0.39 (0.10) 0.48 (0.10) 0.50 (0.12) 0.47 (0.12)
self-management 0.05 (0.02)*** 0.00 (0.02)*** 0.17 (0.07) 0.07 (0.07) 0.01 (0.01) 0.00 (0.01)
Facilitators 0.07 (0.06) 0.14 (0.06) 0.88 (0.20) 0.84 (0.20) 0.01 (0.01) 0.00 (0.01)
Barriers 0.06 (0.03) 0.04 (0.03) 0.52 (0.12) 0.36 (0.12) 0 0
ics, other 0.69 (0.12) 0.71 (0.13) 2.23 (0.47) 1.99 (0.47) 0.06 (0.03) 0.06 (0.03)
Therapeutic: non-ics treatmenta 2.31 (0.27)*** 1.61 (0.27)*** 12.34 (1.32)** 7.46 (1.34)** 1.21 (0.31) 1.33 (0.32)
lifestyle/sociala 0.74 (0.18)*** 0.40 (0.18)*** 3.31 (0.56)** 1.43 (0.57)** 0.17 (0.07) 0.08 (0.07)
smoking 0.22 (0.10) 0.19 (0.10) 0.38 (0.14) 0.18 (0.14) 0.03 (0.02) 0.00 (0.02)
exercise 0.05 (0.03) 0.04 (0.03) 0.43 (0.14) 0.12 (0.14) 0.08 (0.05) 0.05 (0.05)
Weight 0 0 0 0 0 0
nutrition 0.02 (0.01) 0.00 (0.01) 0.11 (0.06) 0.02 (0.06) 0.01 (0.01) 0.00 (0.01)
stress 0 0 0.00 (0.01) 0.02 (0.01) 0 0
Drugs 0.02 (0.02) 0.00 (0.02) 0.05 (0.03) 0.00 (0.03) 0 0
Influenza vaccine 0.02 (0.01) 0.00 (0.01) 0.00 (0.03) 0.04 (0.03) 0 0
living environment 0.15 (0.07) 0.14 (0.07) 0.89 (0.27) 0.41 (0.27) 0.01 (0.01) 0.00 (0.01)
social context 0.07 (0.02) 0.02 (0.02) 1.20 (0.28)*** 0.52 (0.28)*** 0.01 (0.02) 0.04 (0.02)
lifestyle, other 0.19 (0.07)*** 0.01 (0.07)*** 0.30 (0.09) 0.17 (0.09) 0.02 (0.01) 0.00 (0.01)
Psychosocial/feelingsa 0.32 (0.08) 0.25 (0.08) 1.18 (0.26) 1.09 (0.26) 0.03 (0.02) 0.00 (0.02)
ics concerns 0.01 (0.01) 0.00 (0.01) 0.14 (0.04)*** 0.01 (0.04)*** 0 0
ics necessities 0 0 0.08 (0.04) 0.10 (0.04) 0 0
Psychosocial ics, other 0.30 (0.07) 0.20 (0.07) 0.66 (0.15) 0.59 (0.15) 0.03 (0.02) 0.00 (0.02)
non-ics 0.01 (0.03) 0.05 (0.03) 0.29 (0.13) 0.39 (0.13) 0 0
Other 0.41 (0.08)* 0.04 (0.08)* 20.72 (1.52)** 15.09 (1.54)** 0.01 (0.01) 0.00 (0.01)
Totala 18.15 (1.22)* 14.70 (1.22)* 93.31 (5.57)* 61.87 (5.61)* 13.13 (1.57) 12.90 (1.58)
Notes: aTotals have been calculated using the model and can be different from the total of individual categories. *Significant at P,0.001. **Significant at P,0.01. ***Significant 
at P,0.05.
Abbreviations: se, standard error; cOPD, chronic obstructive pulmonary disease; ics, inhaled corticosteroids.
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lifestyle and social context information
Pharmacists gave information about the social context more 
often than technicians. Patients gave information to pharma-
cists more often than to technicians about physical activity 
and the (living) environment.
Psychosocial information/feelings
Pharmacists and technicians differed in giving informa-
tion regarding concerns about ICS, which was mentioned 
on average less than once a session. Patients also differed 
in giving information about this topic; they talked more 
Table 4 Weighted mean (se) of task-oriented behaviors of patients in sessions with pharmacists and pharmacy technicians
Task-oriented communication Question Giving information
Pharmacists’ sessions Technicians’ sessions Pharmacists’ sessions Technicians’ sessions
Medicala 0.33 (0.07)* 0.12 (0.07)* 22.94 (2.20)* 17.01 (2.24)*
Prevalence 0.01 (0.01) 0.00 (0.01) 0 0
Prognosis 0 0 0 0
exacerbations 0 0 0.21 (0.10) 0.15 (0.10)
current health status 0.06 (0.03) 0.06 (0.03) 5.52 (0.53) 4.31 (0.53)
Medical history 0.03 (0.02) 0.01 (0.02) 5.01 (0.66)** 2.24 (0.68)**
heredity 0 0 0.11 (0.12) 0.30 (0.12)
contact other health care providers 
about asthma/cOPD
0.02 (0.01) 0.01 (0.01) 2.83 (0.41) 2.46 (0.42)
lung function test 0.08 (0.06) 0.02 (0.06) 1.86 (0.35) 0.99 (0.36)
explanation about asthma/cOPD 0.07 (0.03) 0.00 (0.03) 0.15 (0.05) 0.06 (0.05)
Medical, other 0.06 (0.02) 0.02 (0.02) 7.33 (1.47) 6.62 (1.49)
Therapeutic: ics treatmenta 2.62 (0.35) 2.28 (0.36) 44.19 (3.08) 40.72 (3.10)
reason for use/need 0.06 (0.05) 0.07 (0.05) 1.19 (0.18) 1.00 (0.18)
Dosage 0.36 (0.10)* 0.08 (0.10)* 5.67 (0.49)*** 3.92 (0.49)***
Adherence 0.04 (0.02) 0.01 (0.02) 1.95 (0.31) 1.43 (0.31)
Medicinal effects 0.15 (0.04) 0.05 (0.04) 2.44 (0.38) 1.82 (0.39)
side-effects 0.24 (0.08) 0.23 (0.08) 3.86 (0.57) 3.91 (0.58)
inhaler/inhalation 1.52 (0.26) 1.64 (0.26) 22.76 (2.11) 22.64 (2.12)
contact other health care providers
about ics
0.08 (0.02) 0.02 (0.02) 1.62 (0.30) 2.11 (0.30)
self-management 0 0 0.16 (0.09) 0.29 (0.09)
Facilitators 0.01 (0.01) 0.01 (0.01) 0.51 (0.15) 0.56 (0.15)
Barriers 0.02 (0.02) 0.02 (0.02) 0.92 (0.19)* 0.34 (0.19)*
ics, other 0.14 (0.04) 0.13 (0.04) 2.81 (0.29) 2.47 (0.29)
Therapeutic: non-ics treatmenta 0.74 (0.15) 0.59 (0.15) 15.21 (1.49) 12.40 (1.52)
lifestyle/sociala 0.17 (0.05)** 0.00 (0.05)** 9.29 (1.43)* 5.74 (1.45)*
smoking 0 0 0.99 (0.31) 0.62 (0.31)
exercise 0.05 (0.02) 0.00 (0.02) 1.99 (0.34)* 1.01 (0.35)*
Weight 0 0 0.00 (0.09) 0.18 (0.09)
nutrition 0 0 0.30 (0.19) 0.33 (0.19)
stress 0 0 0.01 (0.03) 0.04 (0.03)
Drugs 0 0 0.16 (0.08) 0.00 (0.08)
Influenza vaccine 0 0 0.04 (0.06) 0.18 (0.06)
(living) environment 0.07 (0.04) 0.00 (0.04) 1.52 (0.25)** 0.70 (0.25)**
social context 0.05 (0.02)* 0.00 (0.02)* 2.75 (0.67) 1.60 (0.68)
lifestyle, other 0.01 (0.01) 0.00 (0.01) 1.43 (0.37) 0.96 (0.37)
Psychosocial/feelingsa 0.09 (0.04) 0.05 (0.04) 5.84 (0.78) 5.37 (0.79)
ics concerns 0.05 (0.02) 0.02 (0.02) 0.98 (0.21)* 0.45 (0.21)*
ics necessities 0.02 (0.01) 0.00 (0.01) 0.51 (0.13) 0.44 (0.13)
Psychosocial ics, other 0.02 (0.01) 0.01 (0.01) 2.14 (0.37) 2.05 (0.37)
non-ics 0.00 (0.01) 0.01 (0.01) 2.15 (0.55) 2.39 (0.56)
Other 0.44 (0.09) 0.21 (0.09) 17.92 (1.31)** 11.89 (1.34)**
Totala 4.38 (0.49) 3.22 (0.50) 115.40 (6.28)*** 92.77 (6.36)***
Notes: aTotals have been calculated in the model and can be different from the total of individual categories. *Significant at P,0.05. **Significant at P,0.01. ***Significant 
at P,0.001.
Abbreviations: se, standard error; cOPD, chronic obstructive pulmonary disease; ics, inhaled corticosteroids.
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often about ICS concerns in sessions with pharmacists than 
in sessions with technicians.
number of sessions in which topics were 
discussed
Several clinically relevant topics were not discussed during 
many of the counseling sessions (Table S2). The comparison 
between pharmacists and technicians revealed that questions 
about current health status were asked more often by phar-
macists than by technicians, in 26 versus eleven sessions, 
respectively. Pharmacists gave an explanation about asthma 
more than once in 22 sessions; technicians did so in three 
sessions. Pharmacists paid attention more than once to the 
reason for ICS use in 26 sessions and to dosage in 55 sessions, 
whereas technicians only did so in 12 and 25 sessions, respec-
tively. Technicians asked more than once about side effects 
in 42 sessions, whereas pharmacists did so in 29 sessions. 
Lifestyle/social categories were hardly mentioned. Smoking, 
the (living) environment, and the social context were dis-
cussed in a couple of sessions. In addition, psychosocial 
aspects or feelings were seldom discussed.
Outcomes controlled for visit length
As stated before, pharmacists’ sessions lasted longer than 
those of technicians. After controlling for visit length, most 
of the differences between pharmacists and technicians in 
communication behaviors remained significant. This was also 
the case for the differences found in patient communication 
during sessions with pharmacists and technicians after 
controlling for visit length (Table S3).
After controlling for visit length, differences between 
pharmacists’ and technicians’ communication remained sig-
nificant for the following affective categories: social behav-
ior, approval, verbal attention, showing concerns/worry, and 
disagreeing. The differences in the number of questions about 
current health status, heredity, “medical, other”, side effects, 
“lifestyle, other”, and “other” also remained significant. 
In addition, differences in paraphrasing/checking for under-
standing and giving information about the lung function test, 
explanation about asthma/COPD, dosage, medicinal effects, 
and ICS concerns were still significant after controlling for 
visit length, as well as counseling about adherence.
For patient utterances, the number of questions about 
dosage, giving information about medical history, the 
(living) environment, and ICS concerns still differed between 
sessions with pharmacists and technicians after controlling 
for visit length.
Discussion
Many important issues were addressed during the counseling 
sessions. However, pharmacists and technicians could 
pay more attention to some topics. Some differences in 
communication have been found between pharmacists and 
pharmacy technicians.
The counseling sessions consisted largely of instrumental 
talk. Medical and therapeutic topics were frequently dis-
cussed, such as current health status, inhaler and inhalation 
technique, side effects, dosage and time of inhalation, and 
ICS medicinal effects. Pharmacists and pharmacy techni-
cians discussed adherence to a limited degree only. In this 
respect, counseling sessions reflect those of other health care 
providers: this topic is often avoided during patient–provider 
interactions.21,31
Lifestyle and psychosocial issues were hardly addressed 
by pharmacists and technicians, while patients did mention 
these topics. As concerns have relevance for adherence 
to medication,18,39 there might be room for improvement 
in discussing patients’ concerns about ICS and why it is 
necessary to use them. Pharmacists and technicians could 
also pay more attention to lifestyle topics, such as smoking 
habits and exercise.
Pharmacists and technicians talked with the patients 
extensively about the inhaler and inhalation technique, clearly 
the main aim of the session. In addition, medication other than 
ICS (the category “non-ICS treatment”) was often discussed, 
such as bronchodilators (relievers). Because bronchodilators 
are often used in combination with ICS, pharmacists and 
technicians probably discuss these to check the inhalation 
technique as well as the effectiveness of the medication.
Remarkably, patients raised very few questions. On aver-
age, they only asked questions about the inhaler and inhalation 
technique more than once per session. This suggests either 
that they did not have much to ask or that there was not enough 
opportunity to pose questions. Pharmacists and technicians 
could invite patients more explicitly to ask questions.
An important aspect concerning pharmacist–patient 
communication is the way patients view the pharmacists’ 
role (ie, tasks and responsibilities). A few studies have 
shown that some groups of patients have positive views 
about pharmacists’ enhanced role in disease management 
and medication advice.40,41 However, other studies have found 
that patients do not perceive pharmacists as having a signifi-
cant role in patient counseling, medication management, or 
monitoring; patients believe this to be primarily the task of 
physicians.42–44 These findings could be a reason for patients’ 
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possible reticence in posing questions and discussing medi-
cal, lifestyle, and psychosocial issues.
When comparing pharmacists’ and technicians’ sessions, 
pharmacists showed more affective behavior than techni-
cians, and they also discussed some task-oriented topics 
more extensively. Although pharmacists’ sessions lasted 
1.5 times longer than those of technicians, these differences 
could not be fully explained by the longer visit length of 
the pharmacists’ sessions. In contrast to pharmacists and 
technicians, patients did not differ in their affective and 
process-oriented communications when being counseled by 
one or the other professional.
Pharmacist and pharmacy technicians spoke more than 
patients (55.0% and 53.2% of the utterances, respectively). 
Although this indicates that the providers made a greater 
conversational contribution than patients, we think the share 
of provider–patient communication is fairly balanced because 
the percentages are close to the middle (ie, 50%).
We can compare our findings with only a few studies. 
Because of dissimilarities in study setting and health care 
providers, these findings are difficult to compare. When 
comparing our findings with general practitioner–patient 
communication, no remarkable differences were found. 
Pharmacists and technicians in our study showed ~5% more 
affective behavior than general practitioners, which could 
be explained to a large extent by the many agreements that 
pharmacists and technicians expressed.20 General practitio-
ners did not discuss lifestyle/social and psychosocial topics in 
much depth; however, pharmacists and technicians discussed 
them even less. Our findings also confirm the results of a 
simulated patient study of Chong et al25 about antidepres-
sants, which showed that pharmacists’ communication is 
merely focused on biomedical topics and that lifestyle and 
psychosocial topics are underexposed.
To our knowledge, this is the first study about communi-
cation during counseling sessions about ICS in the pharmacy. 
For future research, it would be interesting to study the 
relationship between the communication process and content 
on the one hand and outcomes on the other hand, such as 
patients’ medication adherence, satisfaction, and symptom 
control. In addition, the experiences of patients and health 
care providers with the communication could be taken into 
account, to get insight into which communication styles 
enhance medication optimization, according to them.
strengths and limitations
This study has several strengths. First, exploring the content 
of counseling sessions at the pharmacy has never been done 
before in such an extensive way, resulting in rich informa-
tion about these sessions and an objective and quantitative 
presentation of the content of the verbal communication. 
In addition, this study did not only take pharmacists’ 
communication into account but also looked at technicians’ 
communication and compared the content of the sessions of 
these two categories of professionals.
However, there are some limitations. Selection bias 
could have occurred during pharmacy and patient recruit-
ment. Participating pharmacies could be more engaged in 
patient counseling than the nonparticipating pharmacies, 
and participating patients might be more willing to 
communicate about ICS use, related problems, and feelings. 
In the Netherlands, counseling sessions are not yet routine 
activities in pharmacies,23 which implies that, in general, 
pharmacists and technicians are not very experienced in 
conducting counseling sessions about ICS. Therefore, the 
participating pharmacists and technicians might have better 
counseling skills than their nonparticipating colleagues. 
Hence, the generalizability of the findings is limited.
In addition, the pharmacists sent the invitation letter to 
patients. This might have resulted in bias as patients might 
feel obligated to participate in the study. However, it was 
stated clearly in the letter that participation was voluntary.
Finally, because counseling sessions are not performed 
very frequently, we provided general instructions to the 
pharmacists and technicians about which themes could be 
discussed during the sessions. Although these instructions 
were very broad, they might have influenced our results.
Conclusion
Both pharmacists and pharmacy technicians addressed many 
important medical and therapeutic topics in counseling 
sessions with patients with asthma and/or COPD, but 
they could pay more attention to ICS adherence and to 
lifestyle and psychosocial topics. The two categories of 
professionals differed in their communication: pharmacists 
exhibited more affective behavior than technicians and 
also discussed medical and therapeutic topics in particular 
more extensively.
Practice implications
Educational courses for pharmacists and pharmacy techni-
cians could draw attention to the discussion of ICS adherence, 
lifestyle, and psychosocial topics in patient communication. 
Pharmacy technicians in particular could be encouraged to 
attend to other factors than purely the technical aspects of 
using ICS.
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Supplementary materials
Table S1 examples of statements for riAs categories
RIAS category Examples of statements
Affective part
social behavior At the beginning of the session: Pharmacist: “how are you?”
Approval (Patient shows inhaler technique) Pharmacist: “That looks very good!”
Agreements “hmm, hmm” “Okay”
Verbal attention Pharmacist: “i understand how you must be feeling”
shows concern or worry Patient: “i hope it’s nothing serious”
(Ask for) reassurance Patient: “My asthma is much better”
Disagree Patient: “That’s impossible!”
instrumental part
Process-oriented
Orientations Pharmacist: “can you show me how you use your inhaler, please?”
Paraphrase/check for understanding (Pharmacist: “You have to hold your breath for ten seconds”)
Patient: “Ten seconds?”
Bid for repetition Patient: “What did you say?”
Ask for understanding Pharmacist: “Do you follow?”
Ask for opinion Pharmacist: “Any questions?”
request for services (patient category) Patient: “could you contact the doctor for this, please?” 
Task-oriented communication
Medical Pharmacist: “Do you have asthma?”
Therapeutic Patient: “i take two puffs per day”
lifestyle/social Pharmacist: “Do you smoke?”
Psychosocial/feelings Patient: “i’m worried about the long-term effects of ics”
Other Patient: “Where can I fill in the questionnaire?”
Abbreviations: riAs, roter interaction analysis system; ics, inhaled corticosteroids.
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Table S2 The number of sessions in which a topic is discussed zero times, once, or more than once (divided into questions, giving 
information, and counseling)
Question Giving information Counseling
0 1 .1 0 1 .1 0 1 .1
Medical
Prevalence
Pharmacists 86 0 0 85 0 1 86 0 0
Technicians 83 0 0 83 0 0 83 0 0
Prognosis
Pharmacists 86 0 0 84 2 0 86 0 0
Technicians 83 0 0 83 0 0 83 0 0
exacerbations
Pharmacists 82 3 1 83 2 1 86 0 0
Technicians 83 0 0 82 0 1 83 0 0
current health status
Pharmacists 40 17 29 35 22 29 86 0 0
Technicians 49 23 11 41 20 22 82 1 0
Medical history
Pharmacists 65 13 8 69 10 7 86 0 0
Technicians 69 10 4 72 8 3 83 0 0
heredity
Pharmacists 86 0 0 84 1 1 86 0 0
Technicians 77 4 2 79 2 2 83 0 0
contact other health care providers about asthma/cOPD
Pharmacists 60 15 11 64 12 10 78 4 4
Technicians 56 16 11 69 7 7 70 7 6
lung function test
Pharmacists 72 8 6 62 10 14 81 1 4
Technicians 78 4 1 74 5 4 83 0 0
explanation about asthma/cOPD
Pharmacists 85 1 0 59 5 22 86 0 0
Technicians 83 0 0 79 1 3 83 0 0
Medical, other
Pharmacists 56 10 20 45 10 31 77 6 3
Technicians 69 6 8 55 9 19 80 2 1
Therapeutic: ICS treatment
reason for use/need
Pharmacists 54 25 7 45 15 26 82 4 0
Technicians 64 18 1 59 12 12 81 1 1
Dosage/inhalation
Pharmacists 31 22 33 18 13 55 59 11 16
Technicians 32 29 22 36 22 25 62 13 8
Adherence
Pharmacists 60 19 7 45 16 25 76 8 2
Technicians 55 21 7 49 12 22 67 8 8
Medicinal effects
Pharmacists 40 25 21 10 8 68 84 2 0
Technicians 43 22 18 13 16 54 83 0 0
side effects
Pharmacists 30 27 29 26 10 50 78 5 3
Technicians 16 25 42 18 9 56 81 1 1
inhaler/inhalation
Pharmacists 5 8 73 2 3 81 13 4 69
Technicians 5 4 74 0 1 82 7 7 69
contact other health care providers about ics
Pharmacists 62 17 7 68 8 10 65 7 14
Technicians 57 15 11 60 14 9 62 12 9
self-management
Pharmacists 82 4 0 79 3 4 85 1 0
Technicians 83 0 0 81 0 2 83 0 0
(Continued)
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communication during counseling sessions
Table S2 (Continued)
Question Giving information Counseling
0 1 .1 0 1 .1 0 1 .1
Facilitators
Pharmacists 83 1 2 61 6 19 85 1 0
Technicians 74 7 2 59 11 13 83 0 0
Barriers
Pharmacists 83 2 1 66 6 14 86 0 0
Technicians 80 3 0 71 3 9 83 0 0
ics, other
Pharmacists 49 22 15 28 18 40 82 3 1
Technicians 44 29 10 38 14 31 78 5 0
Therapeutic: non-ICS treatment
Pharmacists 22 18 46 14 6 66 56 13 17
Technicians 31 16 36 14 9 60 55 11 17
Lifestyle/social
smoking
Pharmacists 72 8 6 74 6 6 83 3 0
Technicians 73 6 4 78 3 2 83 0 0
exercise
Pharmacists 83 2 1 71 11 4 82 2 2
Technicians 80 3 0 79 2 2 82 0 1
Weight
Pharmacists 86 0 0 86 0 0 86 0 0
Technicians 83 0 0 83 0 0 83 0 0
nutrition
Pharmacists 85 1 0 83 2 1 85 1 0
Technicians 83 0 0 81 2 0 83 0 0
stress
Pharmacists 86 0 0 86 0 0 86 0 0
Technicians 83 0 0 81 2 0 83 0 0
Drugs
Pharmacists 85 0 1 85 0 1 86 0 0
Technicians 83 0 0 83 0 0 83 0 0
Influenza vaccine
Pharmacists 84 2 0 86 0 0 86 0 0
Technicians 83 0 0 82 0 1 83 0 0
(living) environment
Pharmacists 77 6 3 62 9 15 85 1 0
Technicians 75 5 3 66 7 10 83 0 0
social context
Pharmacists 80 6 0 63 5 18 85 1 0
Technicians 81 2 0 66 4 13 81 1 1
lifestyle, other
Pharmacists 78 5 3 73 7 6 84 2 0
Technicians 82 1 0 73 7 3 83 0 0
Psychosocial/feelings
ics concerns
Pharmacists 85 1 0 79 4 3 86 0 0
Technicians 83 0 0 82 1 0 83 0 0
ics necessities
Pharmacists 86 0 0 82 1 3 86 0 0
Technicians 83 0 0 77 5 1 83 0 0
Psychosocial ics, other
Pharmacists 65 17 4 65 8 13 84 1 1
Technicians 71 8 4 54 18 11 83 0 0
non-ics
Pharmacists 85 1 0 75 5 6 86 0 0
Technicians 81 1 1 72 6 5 83 0 0
Other
Pharmacists 66 11 9 0 0 86 85 1 0
Technicians 79 4 0 0 0 83 83 0 0
Abbreviations: cOPD, chronic obstructive pulmonary disease; ics, inhaled corticosteroids.
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Table S3 Weighted mean (se) of behaviors of pharmacists, pharmacy technicians, and patients, controlled for visit length
Pharmacists’ and technicians’ 
behavior
Patients’ behavior
Pharmacists Technicians Pharmacists’ sessions Technicians’ sessions
Affective part
social behavior 2.11 (0.29)* 1.22 (0.29)* – –
Approval 1.69 (0.17)** 1.29 (0.67)** – –
Agreements 13.86 (1.02) 14.36 (1.02) 12.07 (0.54) 12.36 (0.55)
Verbal attention 0.87 (0.11)*** 0.47 (0.11)*** – –
shows concern or worry 0.09 (0.02)* 0.03 (0.02)* – –
reassurance 1.79 (0.15) 1.76 (0.15) – –
Disagree 0.05 (0.01)* 0.02 (0.01)* – –
instrumental part
Process-oriented
Paraphrase/check for understanding 4.06 (0.35)* 4.76 (0.35)* – –
Task-oriented
Question
Medical
current health status 0.30 (0.05)* 0.18 (0.05)* – –
heredity −0.00 (0.02)** 0.03 (0.02)** – –
Medical, other 0.21 (0.05)* 0.09 (0.05)* – –
ics treatment
reason for use/need 0.12 (0.03) 0.08 (0.03) – –
Dosage – – 0.08 (0.02)* 0.02 (0.02)*
side-effects 0.35 (0.09)*** 0.69 (0.09)*** – –
self-management 0.01 (0.01) 0.00 (0.01) – –
non-ics treatment 0.54 (0.09) 0.54 (0.09) – –
lifestyle/social
social context – – 0.01 (0.00) 0.00 (0.00)
lifestyle, other 0.03 (0.01)* 0.00 (0.01)* – –
Other 0.10 (0.02)*** 0.02 (0.02)*** – –
give information
Medical
Medical history – – 1.00 (0.12)* 0.63 (0.13)*
lung function test 0.22 (0.08)* 0.03 (0.08)* – –
explanation about asthma/cOPD 0.49 (0.10)*** 0.02 (0.10)***
ics treatment
reason for use/need 0.24 (0.04) 0.16 (0.04) – –
Dosage 0.76 (0.09)*** 0.39 (0.09)*** 1.38 (0.14) 1.30 (0.14)
Medicinal effects 1.67 (0.15)** 1.07 (0.15)** – –
inhaler/inhalation 6.02 (0.55) 6.09 (0.55) – –
Barriers – – 0.19 (0.04) 0.09 (0.04)
non-ics treatment 2.63 (0.30) 2.09 (0.31) – –
lifestyle/social
(living) environment – – 0.35 (0.06)* 0.22 (0.06)*
social context 0.25 (0.06) 0.16 (0.06) – –
Psychosocial/feelings
ics concerns 0.03 (0.01)* 0.00 (0.01)* 0.23 (0.05)* 0.11 (0.05)*
Other 4.79 (0.40) 4.82 (0.40) 4.10 (0.32) 3.68 (0.32)
counsel
ics treatment
Adherence 0.05 (0.04)* 0.13 (0.04)* – –
Notes: *Significant at P,0.05. **Significant at P,0.01. ***Significant at P,0.001.
Abbreviations: se, standard error; cOPD, chronic obstructive pulmonary disease; ics, inhaled corticosteroids.
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